[stock_market_widget type=”card” template=”basic2″ assets=”MRNA” realtime=”true” api=”yahoo-finance”]
For years, the idea of designing a cancer treatment around a single person’s tumor sat mostly in research papers and conference talks. That idea took a large step toward the clinic today. Merck & Co., Inc. (NYSE: MRK) and Moderna, Inc. (NASDAQ: MRNA) reported that their experimental, made-to-order vaccine, given alongside Merck’s established immunotherapy Keytruda, helped keep skin cancer from coming back in a large late-stage study.
The study, called INTerpath-001, enrolled 1,137 patients whose melanoma had been removed by surgery, but who still faced a real chance of the disease returning. Participants were split so that two out of every three received the personalized vaccine plus Keytruda, while the rest received Keytruda on its own. At an early planned check of the data, the combination did better on both measures the researchers cared about most: the time patients lived without any recurrence, and the time they lived without the cancer spreading to distant organs. The companies have not yet released the exact numbers, saving those for a medical meeting.
What makes the result notable is not only that it worked but what it represents. This is the first time a personalized cancer vaccine of this type, and the first time any mRNA-based cancer therapy, has succeeded in a final stage trial. It is also the first study to show a clear benefit over Keytruda by itself in patients whose melanoma was surgically removed, a group where that drug alone is already the usual standard of care.
The science is unusual. Each dose is built from a sample of the patient’s own tumor. Researchers read the genetic errors that make that tumor unique, then design a strand of mRNA carrying instructions for as many as 34 of those markers. Once injected, the body reads the code and displays these markers to the immune system, which learns to hunt down cells that carry them. Keytruda helps by taking the brakes off immune cells so they can attack more freely. [1]
Investors reacted fast. Moderna’s shares jumped more than 125% in early trading this morning, among the sharpest single day moves in the company’s history, while Merck climbed roughly 10%. The reaction reflects more than one strong result. Moderna has been hunting for growth as sales of its COVID-19 vaccine fade, and a lasting cancer franchise would give it a very different story to tell. Merck is bracing for the loss of patent protection on Keytruda, its best-selling product, later this decade, so a companion therapy that stretches the drug’s usefulness matters.
Analysts have been sketching the commercial stakes for months. Barclays estimated the therapy could bring in about $3 billion a year for melanoma alone by 2035, and others have suggested peak sales could reach several billion dollars once more cancers are counted. Those numbers hinge on results still to come, since the partners are running nine Phase 2 and Phase 3 trials that test the same method in lung, bladder and kidney cancers. A win in melanoma gives them reason to hope the approach travels.
There are reasons for caution. The trial is still running, and the most important question, whether patients actually live longer, has not been answered. Regulators will want the full data before deciding anything, and the companies say they plan to share results with health authorities and present them publicly in the coming months. The tailored nature of the treatment also raises practical questions about manufacturing and cost that a topline announcement does not resolve.
For an approach that spent a decade as a promising theory, a clean late-stage result changes the conversation. It does not guarantee approval, and it does not tell us how the treatment will fit into everyday care or what it will cost. What it offers is the first solid evidence that a cancer shot tailored to one person can move the needle in a serious disease, and that is why two large drugmakers, and many investors, spent Wednesday paying close attention.
